SUPPLEMENT

Q1 2026 — Other Financial Disclosures

Q1 2026PDF · 13 pages632 KB
Table 1: Sales by Segment 1
Table 2: Sales by Geographic Area 2
Table 3: Sales of Key Products/Franchises 3 - 7
Table 4: Condensed Consolidated Statement of Earnings - QTD 8
Table 5: Non-GAAP Adjusted Operational Sales Growth - QTD 9
Table 6: Non-GAAP Adjusted Net Earnings 10
Table 7: Non-GAAP P&L by Segment Reconciliation 2026 - QTD 11
Table 8: Non-GAAP P&L by Segment Reconciliation 2025 - QTD 12
First Quarter 2026
Other Financial Disclosures
Table of Contents

-- 1 of 13 --

Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
2026 2025 Total Operations Currency
Sales to customers by
segment of business
Innovative Medicine
U.S. 8,871	$ 8,092 9.6 % 9.6 -
International 6,555 5,781 13.4 4.3 9.1
15,426 13,873 11.2 7.4 3.8
MedTech
U.S. 4,459 4,213 5.9 5.9 -
International 4,177 3,807 9.7 3.2 6.5
8,636 8,020 7.7 4.6 3.1
U.S. 13,330 12,305 8.3 8.3 -
International 10,732 9,588 11.9 3.9 8.0
Worldwide 24,062	$ 21,893 9.9 % 6.4 3.5
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
FIRST QUARTER
Percent Change

-- 2 of 13 --

Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
2026 2025 Total Operations Currency
Sales to customers by
geographic area
U.S. 13,330	$ 12,305 8.3 % 8.3 -
Europe 5,848 5,110 14.5 2.7 11.8
Western Hemisphere excluding U.S. 1,293 1,167 10.8 2.5 8.3
Asia-Pacific, Africa 3,591 3,311 8.5 6.1 2.4
International 10,732 9,588 11.9 3.9 8.0
Worldwide 24,062	$ 21,893 9.9 % 6.4 3.5
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
FIRST QUARTER
Percent Change

-- 3 of 13 --

REPORTED SALES vs. PRIOR PERIOD ($MM)
FIRST QUARTER
INNOVATIVE MEDICINE SEGMENT (2) 2026 2025 Reported Operational (1) Currency
ONCOLOGY
US 3,615	$ 3,013 20.0% 20.0% -
Intl 3,358 2,664 26.0% 15.3% 10.7%
WW 6,973 5,678 22.8% 17.8% 5.0%
DARZALEX
US 2,208 1,829 20.7% 20.7% -
Intl 1,756 1,409 24.7% 14.0% 10.7%
WW 3,964 3,237 22.5% 17.8% 4.7%
CARVYKTI
US 433 318 36.2% 36.2% -
Intl 164 51 * * *
WW 597 369 62.1% 57.4% 4.7%
TECVAYLI
US 127 105 20.6% 20.6% -
Intl 74 46 63.1% 52.1% 11.0%
WW 202 151 33.5% 30.1% 3.4%
TALVEY
US 101 68 48.5% 48.5% -
Intl 51 18 * * *
WW 152 86 76.7% 72.8% 3.9%
RYBREVANT / LAZCLUZE
US 175 113 55.1% 55.1% -
Intl 82 28 * * *
WW 257 141 82.7% 80.5% 2.2%
ERLEADA
US 342 292 17.3% 17.3% -
Intl 607 479 26.7% 15.5% 11.2%
WW 949 771 23.1% 16.2% 6.9%
IMBRUVICA
US 143 235 (39.1)% (39.1)% -
Intl 517 474 9.1% (1.4)% 10.5%
WW 660 709 (6.9)% (13.9)% 7.0%
OTHER ONCOLOGY (3)
US 85 54 58.8% 58.8% -
Intl 106 160 (33.9)% (36.3)% 2.4%
WW 192 214 (10.6)% (12.5)% 1.9%
See footnotes at end of schedule
% Change

-- 4 of 13 --

REPORTED SALES vs. PRIOR PERIOD ($MM)
FIRST QUARTER
2026 2025 Reported Operational (1) Currency
IMMUNOLOGY
US 1,855	$ 2,196 (15.5)% (15.5)% -
Intl 1,524 1,510 0.9% (6.4)% 7.3%
WW 3,380 3,707 (8.8)% (11.8)% 3.0%
TREMFYA
US 1,042 599 73.9% 73.9% -
Intl 566 356 58.9% 46.8% 12.1%
WW 1,608 956 68.3% 63.8% 4.5%
SIMPONI / SIMPONI ARIA
US 269 292 (7.8)% (7.8)% -
Intl 378 366 3.0% (4.1)% 7.1%
WW 647 659 (1.7)% (5.7)% 4.0%
REMICADE
US 269 314 (14.4)% (14.4)% -
US Exports (4) 18 10 78.6% 78.6% -
Intl 136 143 (4.8)% (10.5)% 5.7%
WW 422 467 (9.5)% (11.2)% 1.7%
STELARA
US 220 981 (77.6)% (77.6)% -
Intl 435 644 (32.4)% (37.7)% 5.3%
WW 656 1,625 (59.7)% (61.7)% 2.0%
OTHER IMMUNOLOGY
US 38 1 * * -
Intl 9 0 * * *
WW 46 1 * * *
NEUROSCIENCE
US 1,494 968 54.3% 54.3% -
Intl 681 679 0.3% (6.3)% 6.6%
WW 2,175 1,647 32.0% 29.3% 2.7%
SPRAVATO
US 406 276 47.0% 47.0% -
Intl 61 43 42.4% 28.7% 13.7%
WW 468 320 46.4% 44.5% 1.9%
CAPLYTA (5)
US 270 - * * -
Intl - - - - -
WW 270 - * * -
INVEGA SUSTENNA / XEPLION /
INVEGA TRINZA / TREVICTA
US 758 625 21.2% 21.2% -
Intl 280 277 1.1% (4.9)% 6.0%
WW 1,038 903 15.0% 13.2% 1.8%
CONCERTA / Methylphenidate
US 22 38 (43.4)% (43.4)% -
Intl 115 110 4.3% (0.6)% 4.9%
WW 136 148 (8.0)% (11.7)% 3.7%
OTHER NEUROSCIENCE
US 38 28 32.6% 32.6% -
Intl 224 248 (9.7)% (16.3)% 6.6%
WW 262 277 (5.4)% (11.3)% 5.9%
See footnotes at end of schedule
% Change

-- 5 of 13 --

REPORTED SALES vs. PRIOR PERIOD ($MM)
FIRST QUARTER
2026 2025 Reported Operational (1) Currency
PULMONARY HYPERTENSION (PH)
US 831	$ 744 11.7% 11.7% -
Intl 304 281 8.2% 1.0% 7.2%
WW 1,135 1,025 10.7% 8.7% 2.0%
UPTRAVI
US 385 365 5.4% 5.4% -
Intl 98 86 14.3% 5.1% 9.2%
WW 483 451 7.1% 5.4% 1.7%
OPSUMIT / OPSYNVI
US 433 363 19.3% 19.3% -
Intl 172 159 8.7% 1.7% 7.0%
WW 606 522 16.1% 14.0% 2.1%
OTHER PULMONARY HYPERTENSION
US 12 15 (21.1)% (21.1)% -
Intl 34 37 (8.3)% (11.8)% 3.5%
WW 46 52 (12.1)% (14.5)% 2.4%
INFECTIOUS DISEASES (ID)
US 342 315 8.6% 8.6% -
Intl 547 487 12.2% 1.3% 10.9%
WW 889 802 10.8% 4.1% 6.7%
EDURANT / rilpivirine
US 7 8 (13.1)% (13.1)% -
Intl 402 350 14.8% 3.2% 11.6%
WW 409 358 14.1% 2.8% 11.3%
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
US 334 305 9.5% 9.5% -
Intl 109 98 11.2% 0.7% 10.5%
WW 443 403 10.0% 7.4% 2.6%
OTHER INFECTIOUS DISEASES
US 1 2 (56.9)% (56.9)% -
Intl 36 39 (8.3)% (14.7)% 6.4%
WW 37 41 (10.4)% (16.5)% 6.1%
CARDIOVASCULAR / METABOLISM / OTHER (CVM)
US 734 855 (14.2)% (14.2)% -
Intl 142 158 (10.4)% (17.5)% 7.1%
WW 876 1,013 (13.6)% (14.7)% 1.1%
XARELTO
US 642 690 (7.0)% (7.0)% -
Intl - - - - -
WW 642 690 (7.0)% (7.0)% -
OTHER
US 91 165 (44.5)% (44.5)% -
Intl 142 158 (10.4)% (17.5)% 7.1%
WW 233 323 (27.8)% (31.2)% 3.4%
TOTAL PH, ID, CVM
US 1,907 1,914 (0.4)% (0.4)% -
Intl 993 926 7.1% (2.0)% 9.1%
WW 2,899 2,840 2.1% (0.9)% 3.0%
TOTAL INNOVATIVE MEDICINE
US 8,871 8,092 9.6% 9.6% -
Intl 6,555 5,781 13.4% 4.3% 9.1%
WW 15,426	$ 13,873 11.2% 7.4% 3.8%
See footnotes at end of schedule
% Change

-- 6 of 13 --

REPORTED SALES vs. PRIOR PERIOD ($MM)
FIRST QUARTER
MEDTECH SEGMENT (2) 2026 2025 Reported Operational (1) Currency
CARDIOVASCULAR
US 1,399 1,261 10.9% 10.9% -
Intl 978 842 16.1% 9.9% 6.2%
WW 2,377 2,103 13.0% 10.5% 2.5%
ELECTROPHYSIOLOGY
US 736 684 7.6% 7.6% -
Intl 753 638 18.0% 11.7% 6.3%
WW 1,489 1,323 12.6% 9.5% 3.1%
ABIOMED
US 389 339 14.5% 14.5% -
Intl 100 81 23.5% 13.9% 9.6%
WW 488 420 16.3% 14.4% 1.9%
SHOCKWAVE
US 242 206 17.8% 17.8% -
Intl 63 52 21.3% 19.3% 2.0%
WW 305 258 18.5% 18.1% 0.4%
OTHER CARDIOVASCULAR
US 32 32 0.7% 0.7% -
Intl 62 72 (13.4)% (17.5)% 4.1%
WW 94 103 (9.1)% (11.9)% 2.8%
SURGERY
US 1,046 1,002 4.4% 4.4% -
Intl 1,465 1,394 5.1% (1.1)% 6.2%
WW 2,511 2,396 4.8% 1.2% 3.6%
ADVANCED
US 477 457 4.2% 4.2% -
Intl 646 616 4.9% (1.0)% 5.9%
WW 1,123 1,073 4.6% 1.2% 3.4%
GENERAL
US 569 544 4.5% 4.5% -
Intl 819 778 5.2% (1.3)% 6.5%
WW 1,388 1,323 4.9% 1.1% 3.8%
See footnotes at end of schedule
% Change

-- 7 of 13 --

REPORTED SALES vs. PRIOR PERIOD ($MM)
FIRST QUARTER
2026 2025 Reported Operational (1) Currency
VISION
US 579 566 2.4% 2.4% -
Intl 785 713 10.1% 4.6% 5.5%
WW 1,365 1,279 6.7% 3.6% 3.1%
CONTACT LENSES / OTHER
US 468 452 3.7% 3.7% -
Intl 501 467 7.2% 1.7% 5.5%
WW 969 919 5.5% 2.7% 2.8%
SURGICAL
US 111 114 (2.9)% (2.9)% -
Intl 285 246 15.6% 10.1% 5.5%
WW 396 361 9.7% 6.0% 3.7%
ORTHOPAEDICS
US 1,435 1,384 3.7% 3.7% -
Intl 948 857 10.6% 2.4% 8.2%
WW 2,383 2,241 6.3% 3.2% 3.1%
HIPS
US 277 263 5.2% 5.2% -
Intl 159 146 8.9% 0.3% 8.6%
WW 436 409 6.5% 3.5% 3.0%
KNEES
US 239 231 3.3% 3.3% -
Intl 181 158 14.6% 6.5% 8.1%
WW 420 389 7.9% 4.6% 3.3%
TRAUMA
US 532 502 6.1% 6.1% -
Intl 301 270 11.4% 3.1% 8.3%
WW 833 772 8.0% 5.0% 3.0%
SPINE, SPORTS & OTHER
US 387 388 (0.1)% (0.1)% -
Intl 307 283 8.4% 0.7% 7.7%
WW 694 671 3.5% 0.2% 3.3%
TOTAL MEDTECH
US 4,459 4,213 5.9% 5.9% -
Intl 4,177 3,807 9.7% 3.2% 6.5%
WW 8,636	$ 8,020 7.7% 4.6% 3.1%
* Percentage greater than 100% or not meaningful
(1) Operational growth excludes the effect of translational currency
(2) Unaudited
(3) Includes the sales of ZYTIGA which were previously disclosed separately
(4) Reported as U.S. sales
(5) Acquired with Intra-Cellular Therapies on April 2, 2025
Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and,
therefore, may not recalculate precisely
% Change

-- 8 of 13 --

Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except Per Share Figures)
Percent
Percent Percent Increase
Amount to Sales Amount to Sales (Decrease)
Sales to customers 24,062	$ 100.0 21,893	$ 100.0 9.9
Cost of products sold 8,106 33.7 7,357 33.6 10.2
Gross Profit 15,956 66.3 14,536 66.4 9.8
Selling, marketing and administrative expenses 6,034 25.1 5,112 23.3 18.0
Research and development expense 3,527 14.7 3,225 14.7 9.4
In-process research and development impairments 36 0.1 - -
Interest (income) expense, net 43 0.2 (128) (0.6)
Other (income) expense, net 294 1.2 (7,321) (33.4)
Restructuring 32 0.1 17 0.1
Earnings before provision for taxes on income 5,990 24.9 13,631 62.3 (56.1)
Provision for taxes on income 755 3.1 2,632 12.1 (71.3)
Net earnings 5,235	$ 21.8 10,999	$ 50.2 (52.4)
Net earnings per share (Diluted) 2.14	$ 4.54	$ (52.9)
Average shares outstanding (Diluted) 2,445.2 2,423.8
Effective tax rate 12.6 % 19.3 %
Adjusted earnings before provision for taxes and net earnings (1)
Earnings before provision for taxes on income 7,821	$ 32.5 8,011	$ 36.6 (2.4)
Net earnings 6,614	$ 27.5 6,706	$ 30.6 (1.4)
Net earnings per share (Diluted) 2.70	$ 2.77	$ (2.5)
Effective tax rate 15.4 % 16.3 %
(1) See Reconciliation of Non-GAAP Financial Measures.
FIRST QUARTER
2026 2025

-- 9 of 13 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Innovative Medicine MedTech Total
WW As Reported 11.2% 7.7% 9.9%
U.S. 9.6% 5.9% 8.3%
International 13.4% 9.7% 11.9%
WW Currency 3.8 3.1 3.5
U.S. - - -
International 9.1 6.5 8.0
WW Operational 7.4% 4.6% 6.4%
U.S. 9.6% 5.9% 8.3%
International 4.3% 3.2% 3.9%
Caplyta (1.9) (1.2)
U.S. (3.3) (2.2)
International 0.0 0.0
All Other Acquisitions and Divestitures (A&D) 0.1 0.1 0.1
U.S. 0.0 0.2 0.1
International 0.2 0.0 0.1
WW Adjusted Operational Ex A&D 5.6% 4.7% 5.3%
U.S. 6.3% 6.1% 6.2%
International 4.5% 3.2% 4.0%
Adjusted Operational Sales Growth
FIRST QUARTER 2026 ACTUAL vs. 2025 ACTUAL
Segments
Note: Percentages are based on actual, non-rounded figures and may not sum

-- 10 of 13 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
(Dollars in Millions Except Per Share Data) 2026 2025
Net Earnings, after tax- as reported $5,235 $10,999
Pre-tax Adjustments
Intangible Asset Amortization expense 1,247 1,120
Litigation related 330 (6,966)
Orthopaedics Separation related 119 -
Acquisition, integration and divestiture related 96 132
Restructuring related 1 62 55
IPR&D impairments 36 -
(Gains)/losses on securities (59) 39
Tax Adjustments
Tax impact on special item adjustments 2 (424) 1,315
Tax legislation and other tax related (28) 12
Adjusted Net Earnings, after tax $6,614 $6,706
Average shares outstanding (Diluted) 2,445.2 2,423.8
Adjusted net earnings per share (Diluted) $2.70 $2.77
Operational adjusted net earnings per share (Diluted) $2.57
Notes:
1
2
First Quarter
In fiscal 2023, the company initiated a restructuring program of its Orthopaedics franchise within the MedTech segment to streamline operations by exiting
certain markets, product lines and distribution network arrangements. The restructuring expense of $7 million in the fiscal first quarter of 2026 and $55
million in the fiscal first quarter of 2025 primarily includes costs related to market and product exits. This program was substantially completed in Q4 2025.
In fiscal 2025, the company initiated a restructuring program of its Surgery franchise within the MedTech segment to simplify and focus operations by exiting
certain non-strategic product lines and optimize select sites across the network. The restructuring expense of $55 million in the fiscal first quarter of 2026
primarily includes costs related to product exits. This program is expected to be substantially completed by the end of fiscal year 2026.
The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving
at adjusted earnings.

-- 11 of 13 --

Year to Date
Innovative Medicine
First Quarter
Mar. 29, 2026
GAAP
Intangible asset
amortization Litigation related
In-process
research and
development
impairments
Restructuring
related
Acquisition, integration
and divestiture related
(Loss)/gain on
securities
Orthopaedics
Separation Related
Tax legislation
and other tax
related
First Quarter
Mar. 29, 2026
Non-GAAP
Cost of products sold 4,390	$ (763) (10) 3,617	$
Selling, marketing and admin expenses 2,918 2,918
Research and development expense 2,813 2,813
Other segment items (12) (40) (46) 55 (43)
Adjusted Income Before Tax by Segment 5,317 763 40 - - 56 (55) - - 6,121
MedTech
First Quarter
Mar. 29, 2026
GAAP
Intangible asset
amortization Litigation related
In-process
research and
development
impairments
Restructuring
related
Acquisition, integration
and divestiture related
(Loss)/gain on
securities
Orthopaedics
Separation Related
Tax legislation
and other tax
related
First Quarter
Mar. 29, 2026
Non-GAAP
Cost of products sold 3,701	$ (484) (25) 3,192	$
Selling, marketing and admin expenses 2,906 2,906
Research and development expense 714 714
Other segment items 76 41 (36) (37) (27) 4 (119) (98)
Adjusted Income Before Tax by Segment 1,239 484 (41) 36 62 27 (4) 119 - 1,922
Expenses not allocated to segments
First Quarter
Mar. 29, 2026
GAAP
Intangible asset
amortization Litigation related
In-process
research and
development
impairments
Restructuring
related
Acquisition, integration
and divestiture related
(Loss)/gain on
securities
Orthopaedics
Separation Related
Tax legislation
and other tax
related
First Quarter
Mar. 29, 2026
Non-GAAP
Cost of products sold 15	$ 15	$
Selling, marketing and admin expenses 210 210
Research and development expense - -
Other segment items 341 (331) (13) (3)
Adjusted Income Before Tax by Segment (566) - 331 - - 13 - - - (222)
Johnson & Johnson Consolidated
First Quarter
Mar. 29, 2026
GAAP
Intangible asset
amortization Litigation related
In-process
research and
development
impairments
Restructuring
related
Acquisition, integration
and divestiture related
(Loss)/gain on
securities
Orthopaedics
Separation Related
Tax legislation
and other tax
related
First Quarter
Mar. 29, 2026
Non-GAAP
Cost of products sold 8,106	$ (1,247) (25) (10) 6,824	$
Selling, marketing and admin expenses 6,034 6,034
Research and development expense 3,527 3,527
Other (Income) / Expense 294 (330) (5) (86) 59 (119) (187)
In-process research and development impairments 36 (36) -
Interest (Income)/Expense 43 43
Restructuring 32 (32) -
Adjusted Income Before Tax 5,990 1,247 330 36 62 96 (59) 119 - 7,821
Provision for taxes on income 755 240 72 8 70 22 (13) 25 28 1,207
Net Earnings 5,235	$ 1,007 258 28 (8) 74 (46) 94 (28) 6,614
Johnson & Johnson and Subsidiaries
GAAP to Non-GAAP Reconciliation
$ in Millions

-- 12 of 13 --

Innovative Medicine
First Quarter
March 30, 2025
GAAP
Intangible asset
amortization Litigation related
Restructuring
related
Acquisition, integration
and divestiture related
(Loss)/gain on
securities
Tax legislation
and other tax
related
First Quarter
March 30, 2025
Non-GAAP
Cost of products sold 4,020	$ (649) 3,371
Selling, marketing and admin expenses 2,261 2,261
Research and development expense 2,548 2,548
Other segment items (166) - - - (20) (18) - (204)
Adjusted Income Before Tax by Segment 5,210 649 - - 20 18 - 5,897
MedTech
First Quarter
March 30, 2025
GAAP
Intangible asset
amortization Litigation related
Restructuring
related
Acquisition, integration
and divestiture related
(Loss)/gain on
securities
Tax legislation
and other tax
related
First Quarter
March 30, 2025
Non-GAAP
Cost of products sold 3,326	$ (471) (8) (52) 2,795
Selling, marketing and admin expenses 2,656 2,656
Research and development expense 677 (6) 671
Other segment items (60) - - (47) (54) (21) - (182)
Adjusted Income Before Tax by Segment 1,421 471 - 55 112 21 - 2,080
Expenses not allocated to segments
First Quarter
March 30, 2025
GAAP
Intangible asset
amortization Litigation related
Restructuring
related
Acquisition, integration
and divestiture related
(Loss)/gain on
securities
Tax legislation
and other tax
related
First Quarter
March 30, 2025
Non-GAAP
Cost of products sold 11	$ 11
Selling, marketing and admin expenses 195 195
Research and development expense -
Other segment items (7,206) - 6,966 - - - - (240)
Adjusted Income Before Tax by Segment 7,000 - (6,966) - - - - 34
Johnson & Johnson Consolidated
First Quarter
March 30, 2025
GAAP
Intangible asset
amortization Litigation related
Restructuring
related
Acquisition, integration
and divestiture related
(Loss)/gain on
securities
Tax legislation
and other tax
related
First Quarter
March 30, 2025
Non-GAAP
Cost of products sold 7,357	$ (1,120) (8) (52) - 6,177
Selling, marketing and admin expenses 5,112 5,112
Research and development expense 3,225 (6) 3,219
Other (Income) / Expense (7,321) - 6,966 (30) (74) (39) (498)
In-process research and development impairments - -
Interest (Income)/Expense (128) (128)
Restructuring 17 (17) -
Adjusted Income Before Tax 13,631 1,120 (6,966) 55 132 39 - 8,011
Provision for taxes on income 2,632 188 (1,553) 11 30 9 (12) 1,305
Net Earnings 10,999 932 (5,413) 44 102 30 12 6,706
Johnson & Johnson and Subsidiaries
GAAP to Non-GAAP Reconciliation
$ in Millions
Year to Date

-- 13 of 13 --